Frontiers in Cellular and Infection Microbiology ( IF 4.6 ) Pub Date : 2020-06-03 , DOI: 10.3389/fcimb.2020.00335 Jiezuan Yang 1 , Renyong Guo 2 , Dong Yan 1 , Haifeng Lu 1 , Hua Zhang 1 , Ping Ye 1 , Linfeng Jin 1 , Hongyan Diao 1 , Lanjuan Li 1
The ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin motif repeats 13) is a key factor involved in coagulation process and plays a vital role in the progression and prognosis of chronic hepatitis B (CHB) patients with antiviral treatment. However, there are few reports about the profile of plasma ADAMTS13 in CHB patients during entecavir maleate (m-ETV) treatment. One hundred two HBV e antigen (HBeAg)–positive CHB patients on continuous m-ETV naive for at least 96 weeks were recruited. Patients with liver cirrhosis were excluded using liver biopsies and real-time elastography. Plasma ADAMTS13 and interleukin 12 (IL-12) levels were evaluated at baseline and12, 24, 48, 72, and 96 weeks, respectively. The change of ADAMTS13 (ΔADAMTS13) and IL-12 (ΔIL-12) possesses a significant relationship in CHB patients with HBeAg seroconversion (SC) at 48-week m-ETV treatment (
中文翻译:
ADAMTS13 或 IL-12 的血浆水平作为接受 m-ETV 治疗的慢性乙型肝炎患者 HBeAg 血清转换的指标。
ADAMTS13(一种具有血小板反应蛋白基序重复 13 次的去整合素和金属蛋白酶)是参与凝血过程的关键因素,在接受抗病毒治疗的慢性乙型肝炎 (CHB) 患者的进展和预后中起着至关重要的作用。然而,关于马来酸恩替卡韦 (m-ETV) 治疗期间慢性乙型肝炎患者血浆 ADAMTS13 分布的报道很少。招募了 102 名 HBV e 抗原 (HBeAg) 阳性的慢性乙型肝炎患者,这些患者连续接受 m-ETV 治疗至少 96 周。使用肝活检和实时弹性成像排除肝硬化患者。分别在基线和 12、24、48、72 和 96 周评估血浆 ADAMTS13 和白细胞介素 12 (IL-12) 水平。